Papillary Thyroidcarcinoma in Rats After Administration of Platinum Compounds Daily

Abstract

Papillary thyroid carcinoma (PTC) predominantly grows in a solid growth pattern with papillary projections, composed of oncocytic cells with “Orphan annie eyes” nuclei. Cisplatin or Cis-Diammine dichloroplatinum (ii) (Cl₂H₆N₂Pt); is a divalent, inorganic and water-soluble first successful platinum containing anticancer drug, used to treat various forms of cancers. The Carboplatin (C₆H₁₄N₂O₄Pt) and Oxaliplatin (C₈H₁₄N₂O₄Pt) are the investigational chemotherapy medicines, belonging to platinum analogue interfere as the Cisplatin with the genetic material or DNA inside the cancer cells and prevent them from further dividing and growing more cancer cells by forming interstrand and intrastrand cross-linking of DNA molecules. The effect of the intraperitoneal injection of all these three compounds at the dose level 5 mg/Kg BW (Group-A), 5 mg/Kg BW (Group-B), 5 mg/Kg BW (Group-C) were studied, however, among the three groups Group-A and B resulted in the formation of papillary thyroid carcinoma (PTC), the severity of PTC was found to be higher in Group-A than in Group-B. In the present study the PTC was characterized by follicles without colloid, cells were arranged in clusters, with nuclear crowding and overlapping, some cells still demonstrated a polygonal contour with well-defined central nucleus, finely granular, delicate, powdery chromatin, presence of multinucleated giant cells or a row of palisaded tumor cells with empty lumen, whereas, Group-C resulted into Hürthle cell carcinoma (HCC).

Keywords: Papillary thyroid carcinoma (PTC), thyroid gland, cisplatin, carboplatin, oxaliplatin

Cite this Article

Sastry MS, Snehal Dighade. Papillary thyroidcarcinoma in rats after administration of platinum compounds daily. Research and Reviews: Journal of Medicine. 2015; 5(3): 27–31p.